Epidermal Growth Factor Receptor (EGFR)

First-line Afatinib Benefits Lung Cancer Patients With Brain Metastases

By

For patients with non-small cell lung cancer who have EGFR mutations and brain metastases, progression-free survival was improved with afatinib compared to chemotherapy.

LUX-Lung 7 Trials Shows Afatinib Achieves Better Response Than Gefitinib in Patients With EGFR-mutated Lung Cancer

By

In the global, randomized, open-label phase IIb LUX-Lung 7 trial, efficacy across a range of clinically relevant end points, such as progression-free survival, time-to-treatment failure, and objective response rate, was significantly improved with afatinib vs. gefitinib.

First-in-class antibody shows clinical activity against advanced colorectal cancer

By

Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies, was found to be clinically active in patients with advanced colorectal cancer that had become anti-EGFR therapy resistant.

Frequency of EGFR mutations is higher among the Asian population

By

A recent study has found that, within the Asian population, the frequency of epidermal growth factor receptor mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking.

Potential new drug for advanced lung cancers resistant to existing EGFR inhibitors

By

The investigational drug AZD9291, a third-generation epidermal growth factor receptor (EGFR) inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.

A roundup of FDA news from July 2013

By

The FDA has granted orphan drug designation to a cancer stem cell inhibitor known as VS-6063, or defactinib, for use in the treatment of mesothelioma, a rare form of lung cancer.

Managing skin effects of EGFR inhibitor ­therapy

Managing skin effects of EGFR inhibitor ­therapy

By

Which patients, if any, should receive prophylactic antibiotics when starting therapy with epidermal growth factor receptor (EGFR) inhibitors?

Further research needed into lung cancer in female never-smokers

By

Lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor overexpression, according to a new study.

Prognosis is worse for NSCLC patients with EGFR exon 20 insertions

By

Patients with epidermal growth factor receptor (EGFR) exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but have a poorer response, according to a recent study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs